US 12,129,289 B2
Antibodies specific for hyperphosphorylated tau and methods of use thereof
Jan Torleif Pedersen, Valby (DK); Kristian Kjaergaard, Valby (DK); Lars Østergaard Pedersen, Valby (DK); Ayodeji Abdur-Rasheed Asuni, Valby (DK); Nina Helen Rosenqvist, Valby (DK); Justus Claus Alfred Daechsel, Valby (DK); Karsten Juhl, Greve (DK); Lena Tagmose, Lyngby (DK); Mauro Marigo, Skovlunde (DK); Thomas Jensen, Copenhagen (DK); Søren Christensen, Valby (DK); Laurent David, Valby (DK); Christiane Volbracht, Valby (DK); and Lone Helboe, Valby (DK)
Assigned to H. Lundbeck A/S, Valby (DK)
Filed by H. Lundbeck A/S, Valby (DK)
Filed on Aug. 11, 2021, as Appl. No. 17/399,205.
Application 17/399,205 is a continuation of application No. 16/585,207, filed on Sep. 27, 2019, granted, now 11,111,290.
Application 16/585,207 is a continuation of application No. 15/645,442, filed on Jul. 10, 2017, granted, now 10,472,415.
Claims priority of application No. PA201600416 (DK), filed on Jul. 12, 2016; application No. PA201700005 (DK), filed on Jan. 4, 2017; application No. PA201700008 (DK), filed on Jan. 4, 2017; and application No. PA201700179 (DK), filed on Mar. 14, 2017.
Prior Publication US 2022/0177557 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 39/395 (2006.01); A61K 49/00 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/395 (2013.01); A61K 49/00 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2800/2814 (2013.01); G01N 2800/2821 (2013.01)] 15 Claims
 
1. A monoclonal antibody, or an epitope-binding fragment thereof, comprising:
(a) a Light Chain CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:40; and SEQ ID NO:46;
(b) a Light Chain CDR2 comprising the amino acid sequence of SEQ ID NO:4; SEQ ID NO:41; and SEQ ID NO:47;
(c) a Light Chain CDR3 comprising the amino acid sequence of SEQ ID NO:5; SEQ ID NO:42; and SEQ ID NO:48;
(d) a Heavy Chain CDR1 comprising the amino acid sequence of SEQ ID NO:6; SEQ ID NO:43; SEQ ID NO:49; SEQ ID NO:52; and SEQ ID NO:55;
(e) a Heavy Chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:44; SEQ ID NO:50; SEQ ID NO:53; and SEQ ID NO:56;
and
(f) a Heavy Chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:39; SEQ ID NO:45; SEQ ID NO:51; SEQ ID NO:54; and SEQ ID NO:57.